References
- From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017 Available from: http://goldcopd.org. Accessed 1116, 2017.
- Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017;(293):1–8.
- Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-097225058738
- Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011;20(3):257–268. doi:10.4104/pcrj.2011.0002921472192
- Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.0020021223722616
- van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Out. 2003;1:13. doi:10.1186/1477-7525-1-13
- Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Resp Med. 2000;94:589–596. doi:10.1053/rmed.2000.0786
- Reilly M, Zbrozek A, Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–365. doi:10.2165/00019053-199304050-0000610146874
- Smid DE, Franssen FME, Houben-Wilke S, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. JAMDA. 2017;18:53–58. doi:10.1016/j.jamda.2016.08.00227624705
- Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax. 2014;69(9):793–798. doi:10.1136/thoraxjnl-2013-20411924149828
- Bisca GW, Proença M, Salomão A, Hernandes NA, Pitta F. Minimal detectable change of the London chest activity of daily living scale in patients with COPD. J Cardiopulm Rehabil Prev. 2014;34:213–216. doi:10.1097/HCR.000000000000004724531202
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107. doi:10.1002/sim.369719757444
- Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. Development of a COPD severity score. Curr Med Res Opin. 2006;22(9):1679–1687. doi:10.1185/030079906X11562116968571
- Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq43321330339
- Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
- Chapman KR, Bateman ED, Chen H, Hu H, Fogel R, Banerji D. QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: a subgroup analysis from the SHINE and ILLUMINATE studies. J Copd F. 2015;2(1):48–60. doi:10.15326/jcopdf.2.1.2014.0140